ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.
Also NCI prostate SPOREs plan biospecimen bank.
NCI advisors seek comment on clinical trials system, until Jan. 15.
NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.
Dept. of Defense opens program announcements for prostate cancer research.
Children’s Cancer Research Institute at UT Health Science Center recruits faculty.
Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.
December issue of Business & Regulatory Report included (an additional 8 pages of industry news).
Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.
Trending Stories
- Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed - As fire encroached, City of Hope prepared to evacuate its Duarte campus
- NCCN publishes patient resource on genetic testing to guide patient decisionmaking
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Trump 2016: A look back at the 45th president’s impact on oncology
- FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials
